177Lu-DOTATATE 肽受体放射性核素治疗神经内分泌肿瘤骨转移患者的临床结局:真实世界经验启示
本研究回顾性分析了74例分化良好的神经内分泌肿瘤骨转移患者接受177Lu-DOTATATE肽受体放射性核素治疗的真实世界结局,共288个周期,中位累积活度21.3 GBq。可评估的62例中,骨转移灶最佳客观缓解率31%、总体缓解率23%,骨痛缓解率较高,4/5级不良事件发生率12%。中位无进展生存期29个月、总生存期44个月;累积活度≥29.6 GBq与更好的无进展生存期和总生存期独立相关。
要点
- 骨转移灶客观缓解率31%,总体缓解率23%,骨转移负荷(≤10 vs >10处)对缓解率无显著影响。
- 23例骨痛患者中39%完全缓解、52%部分减轻;4/5级不良事件发生率12%。
- 中位无进展生存期29个月、总生存期44个月;累积活度≥29.6 GBq是最强独立预测因素。
核心结论
- 177Lu-DOTATATE肽受体放射性核素治疗对神经内分泌肿瘤骨转移患者是有效治疗方式(无论转移负荷如何),具有良好安全性和生存结局。
- 该队列中监测血清碱性磷酸酶至关重要。
- 达到最佳累积活度对最大化肽受体放射性核素治疗的生存获益至关重要。
研究设计与样本
- 回顾性审查本中心2014年1月至2024年8月连续接受177Lu-DOTATATE治疗的分化良好神经内分泌肿瘤骨转移患者资料。
- 共74例患者接受288个肽受体放射性核素治疗周期;中位周期数4(四分位距2-6),中位累积活度21.3 GBq(四分位距11.1-33.3 GBq)。
- 分析安全性、疗效、无进展生存期和总生存期结局。
主要发现
- 62例可评估患者中,采用改良M.D. Anderson标准(骨转移灶)和RECIST 1.1(总体缓解)评估的最佳客观缓解率分别为31%和23%。
- 骨转移负荷(≤10 vs >10处)对客观缓解率无显著影响。
- 23例(31%)有骨痛的患者中,39%报告完全缓解,52%经历部分减轻。
- 4级或5级不良事件发生于12%的患者,贫血、血小板减少、白细胞减少和中性粒细胞减少各发生于不到5%的患者;20%的患者记录到骨骼相关事件。
- 中位无进展生存期29个月(95%CI 18.0-39.9个月),中位总生存期44个月(95%CI 32.8-55.2个月)。
关键数值与推荐
- 多因素Cox回归分析显示,较高累积活度(≥29.6 GBq)是改善无进展生存期(HR 0.15;P<0.001)和总生存期(HR 0.11;P<0.001)的最强独立预测因素。
- 血清碱性磷酸酶升高(HR 2.68;P=0.048)和男性(HR 3.48;P=0.007)与更差的总生存率相关。
临床怎么用
- 原文结论指出,177Lu-DOTATATE肽受体放射性核素治疗对神经内分泌肿瘤骨转移患者是有效治疗方式(无论转移负荷如何),具有良好安全性和生存结局。
- 原文结论指出,该患者队列中监测血清碱性磷酸酶至关重要。
- 原文结论指出,达到最佳累积活度对最大化肽受体放射性核素治疗的生存获益至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Skeletal metastases portend a poor prognosis for patients with neuroendocrine tumors (NETs). Literature on peptide receptor radionuclide therapy (PRRT) specific to patients with skeletal metastases from NETs is scarce. This study assessed real-world clinical outcomes of 177Lu-DOTATATE PRRT in this patient subgroup. Methods: Data from consecutive patients with well-differentiated NETs and skeletal metastases treated with 177Lu-DOTATATE at our center from January 2014 until August 2024 were retrospectively reviewed. Safety, efficacy, progression-free survival (PFS), and overall survival (OS) outcomes were analyzed. Results: In total, 288 PRRT cycles were administered to 74 patients. The median number of PRRT cycles was 4 (interquartile range, 2-6), and the median cumulative activity was 21.3 GBq (interquartile range, 11.1-33.3 GBq). The best objective response rates, evaluated using modified M.D. Anderson criteria (bone metastases) and RECIST 1.1 (overall response), were 31% and 23%, respectively, for 62 evaluable patients. The skeletal metastases burden (≤10 vs. >10 sites) did not significantly affect objective response rates. Among the 23 patients with bone pain (31%), 39% reported complete resolution and 52% experienced a partial reduction after treatment. Grade 4 or 5 adverse events occurred in 12% of patients, with anemia, thrombocytopenia, leukopenia, and neutropenia each occurring in fewer than 5% of patients. Skeletal-related events were noted in 20% of patients. The median PFS and OS were 29 mo (95% CI, 18.0-39.9 mo) and 44 mo (95% CI, 32.8-55.2 mo), respectively. Multivariate Cox regression analysis revealed that higher cumulative activity (≥29.6 GBq) was the strongest independent predictor of improved PFS (hazard ratio [HR], 0.15; P < 0.001) and OS (HR, 0.11; P < 0.001), whereas serum alkaline phosphatase elevation (HR, 2.68; P = 0.048) and male sex (HR, 3.48; P = 0.007) were associated with worse OS rates. Conclusion: 177Lu-DOTATATE PRRT is an effective treatment modality for patients with skeletal metastases from NETs (regardless of metastatic burden), with a favorable safety profile and favorable survival outcomes. Serum alkaline phosphatase monitoring is essential in this patient cohort. Achieving an optimal cumulative activity is crucial to maximizing the survival benefit of patients receiving PRRT.
引用
- Chandekar KR, Satapathy S, Ballal S, et al. Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience. J Nucl Med. 2025. PMID: 40404399. doi:10.2967/jnumed.125.269456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。